Prostate tumors, resistant to current antiandrogen therapies, represent a serious clinical challenge. A new report identifies androgen-receptor-dependent liquid condensates as being responsible in part for therapeutic resistance, but, encouragingly, also reveals a novel vulnerability amenable to drug targeting.
References
Wang, B. et al. Signal Transduct. Target. Ther. 6, 290 (2021).
Stortz, M., Presman, D. M., Pecci, A., Levi, V. & Ruggieri, A. Biochem J. 478, 443–461 (2021).
Xie, J. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-022-01151-y (2022).
McEwan, I. J. Mol. Biosyst. 8, 82–90 (2012).
Asangani, I. et al. J. Biol. Chem. 296, 100240 (2021).
Bouchard, J. J. et al. Mol. Cell 72, 19–36 (2018).
Bielskutė, S. et al. Protein Sci. 30, 1427–1437 (2021).
Ahmed, J., Meszaros, A., Lazar, T. & Tompa, P. Protein Sci. 30, 1380–1392 (2021).
Andersen, R. J. et al. Cancer Cell 17, 535–546 (2010).
Ruggieri, A. & Stoecklin, G. Nat. Chem. Biol. 15, 5–6 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
McEwan, I.J. Breaking apart condensates. Nat Chem Biol 18, 1292–1293 (2022). https://doi.org/10.1038/s41589-022-01161-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-022-01161-w
- Springer Nature America, Inc.